Changes in B- And T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis

Archives of Neurology
doi 10.1001/archneurol.2010.99
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Transplantation Tolerance Correlates With High Levels of T- And B-Lymphocyte Activity.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1989English

Aging and Lymphocyte Changes by Immunomodulatory Therapies Impact PML Risk in Multiple Sclerosis Patients

Multiple Sclerosis
Neurology
2018English

Rituximab in Multiple Sclerosis at General Hospital Level

Acta Neurologica Scandinavica
MedicineNeurology
2020English

Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis

Current Drug Target -Inflammation & Allergy
2004English

Experience With Long-Term Rituximab Use in a Multiple Sclerosis Clinic

Multiple Sclerosis Journal – Experimental, Translational and Clinical
2016English

Lymphocyte Response Depressive Factor in Multiple Sclerosis

BMJ
1971English

B Cells in Multiple Sclerosis

Autoimmunity
AllergyImmunology
2017English

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study

Journal of Immunology Research
MedicineAllergyImmunology
2018English

Women With Recurrent Vaginal Candidosis Have Normal Peripheral Blood B and T Lymphocyte Subset Levels.

Sexually Transmitted Infections
DermatologyInfectious Diseases
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy